Analyst Ratings for [BIIB] Biogen Inc.

2/11/25	Initiated	Mkt Perform	X
BIIB Biogen Bernstein
$160
1/2/25	Downgrades	Overweight Neutral		X
BIIB Biogen Piper Sandler
$315 $138
12/20/24	Downgrades	Outperform Mkt Perform		X
BIIB Biogen BMO Capital Markets
$230 $164
12/16/24	Downgrades	Buy Hold	X
BIIB Biogen Stifel
$175
12/10/24	Resumed	Neutral		X
BIIB Biogen BofA Securities
$178
12/9/24	Downgrades	Buy Hold		X
BIIB Biogen Jefferies
$250 $180
11/18/24	Downgrades	Buy Hold	X
BIIB Biogen Needham
11/15/24	Initiated	Peer Perform		X
BIIB Biogen Wolfe Research
11/14/24	Initiated	Neutral	X
BIIB Biogen Citigroup
$190
10/31/24	Downgrades	Overweight Eq-Weight		X
BIIB Biogen Morgan Stanley
$285 $204
10/10/24	Resumed	Mkt Perform		X
BIIB Biogen Raymond James
2/14/24	Reiterated	Buy	X
BIIB Biogen Needham
$305 $300
2/14/24	Downgrades	Overweight Eq Weight		X
BIIB Biogen Wells Fargo
$315 $240
1/24/24	Downgrades	Buy Neutral		X
BIIB Biogen UBS
$311 $276
12/7/23	Upgrades	Mkt Perform Outperform	X
BIIB Biogen Raymond James
$283
9/6/23	Initiated	Buy		X
BIIB Biogen HSBC Securities
$360
7/27/23	Initiated	Sector Outperform		X
BIIB Biogen Scotiabank
$327
7/24/23	Reiterated	Buy	X
BIIB Biogen UBS
$346 $335
5/1/23	Upgrades	Neutral Buy		X
BIIB Biogen Guggenheim
$270 $350
4/17/23	Upgrades	Neutral Overweight		X
BIIB Biogen Piper Sandler
$280 $346
10/26/22	Upgrades	Neutral Buy	X
BIIB Biogen Goldman
$220 $370
10/13/22	Upgrades	Hold Buy		X
BIIB Biogen Stifel
$223 $299
10/7/22	Upgrades	Hold Buy		X
BIIB Biogen Argus
$300
9/28/22	Upgrades	Mkt Perform Outperform	X
BIIB Biogen BMO Capital Markets
$217 $360
9/28/22	Upgrades	Neutral Buy		X
BIIB Biogen Mizuho
$207 $270
9/28/22	Upgrades	Neutral Outperform		X
BIIB Biogen Robert W. Baird
$224 $340
4/18/22	Upgrades	Eq Weight Overweight	X
BIIB Biogen Wells Fargo
$235 $265
3/8/22	Downgrades	Buy Hold		X
BIIB Biogen Stifel
$304 $223
2/4/22	Reiterated	Equal Weight		X
BIIB Biogen Barclays
$244 $235
2/4/22	Downgrades	Outperform Mkt Perform	X
BIIB Biogen BMO Capital Markets
$260 $238
2/4/22	Reiterated	Neutral		X
BIIB Biogen BofA Securities
$245 $230
2/4/22	Reiterated	Buy		X
BIIB Biogen Needham
$292 $290
2/4/22	Reiterated	Outperform	X
BIIB Biogen Oppenheimer
$350 $285
2/4/22	Reiterated	Sector Perform		X
BIIB Biogen RBC Capital Mkts
$225 $227
2/4/22	Reiterated	Equal Weight		X
BIIB Biogen Wells Fargo
$284 $235
2/4/22	Reiterated	Peer Perform	X
BIIB Biogen Wolfe Research
$244 $217
1/12/22	Downgrades	Overweight Neutral		X
BIIB Biogen Piper Sandler
$362 $216
12/10/21	Resumed	Mkt Perform		X
BIIB Biogen Raymond James
12/9/21	Resumed	Equal Weight	X
BIIB Biogen Wells Fargo
$250
11/19/21	Initiated	Outperform		X
BIIB Biogen BMO Capital Markets
$315
6/18/21	Upgrades	Neutral Overweight		X
BIIB Biogen Piper Sandler
$384 $450
6/14/21	Reiterated	Buy	X
BIIB Biogen Truist
$458 $647
6/11/21	Upgrades	Mkt Perform Outperform		X
BIIB Biogen Bernstein
$500
6/8/21	Upgrades	Underweight Neutral		X
BIIB Biogen Atlantic Equities
$415
6/8/21	Upgrades	Sell Neutral	X
BIIB Biogen Citigroup
$200 $440
6/8/21	Upgrades	Underperform Neutral		X
BIIB Biogen Robert W. Baird
$216 $382
2/5/21	Downgrades	Buy Hold		X
BIIB Biogen DZ Bank
$264
1/29/21	Upgrades	Hold Buy	X
BIIB Biogen Stifel
$258 $358
6/28/19	Downgrades	Overweight Neutral		X
BIIB Biogen Piper Jaffray
$280 $250
6/5/19	Upgrades	Hold Buy		X
BIIB Biogen Standpoint Research
5/23/19	Resumed	Neutral	X
BIIB Biogen Citigroup
5/23/19	Initiated	Neutral		X
BIIB Biogen Wedbush
5/21/19	Initiated	Underperform	X
BIIB Biogen Credit Suisse
$198
4/10/19	Resumed	Mkt Perform		X
BIIB Biogen Raymond James
3/25/19	Reiterated	Buy		X
BIIB Biogen H.C. Wainwright
$363 $300
3/22/19	Reiterated	Market Perform	X
BIIB Biogen BMO Capital Markets
$322 $250
3/22/19	Downgrades	Buy Hold		X
BIIB Biogen Canaccord Genuity
$396 $275
3/22/19	Downgrades	Overweight Underweight		X
BIIB Biogen Morgan Stanley
$401 $210
3/22/19	Downgrades	Buy Neutral	X
BIIB Biogen UBS
$395 $242
3/21/19	Downgrades	Overweight Neutral		X
BIIB Biogen Atlantic Equities
3/21/19	Downgrades	Buy Neutral		X
BIIB Biogen BofA/Merrill
3/21/19	Downgrades	Buy Neutral	X
BIIB Biogen Goldman
3/21/19	Reiterated	Neutral		X
BIIB Biogen Guggenheim
$325
3/21/19	Downgrades	Overweight Neutral	X
BIIB Biogen JP Morgan
3/21/19	Downgrades	Buy Neutral		X
BIIB Biogen Mizuho
3/21/19	Downgrades	Outperform Mkt Perform	X
BIIB Biogen Wells Fargo
3/21/19	Downgrades	Outperform Mkt Perform		X
BIIB Biogen William Blair
2/21/19	Downgrades	Buy Hold	X
BIIB Biogen Stifel
$397 $346
12/21/18	Initiated	Buy		X
BIIB Biogen BTIG Research
10/19/18	Downgrades	Outperform Mkt Perform		X
BIIB Biogen Bernstein
10/8/18	Reiterated	Buy	X
BIIB Biogen Citigroup
$483 $470
10/1/18	Resumed	Overweight		X
BIIB Biogen Cantor Fitzgerald
$400
8/7/18	Resumed	Buy		X
BIIB Biogen Stifel
$394
7/25/18	Reiterated	Buy	X
BIIB Biogen SunTrust
$321 $392
7/10/18	Downgrades	Outperform Neutral		X
BIIB Biogen Robert W. Baird
7/6/18	Upgrades	Neutral Buy		X
BIIB Biogen Citigroup
5/31/18	Upgrades	Hold Buy	X
BIIB Biogen Canaccord Genuity
$350 $335
4/25/18	Upgrades	Neutral Outperform		X
BIIB Biogen Robert W. Baird
4/5/18	Downgrades	Overweight Eq Weight		X
BIIB Biogen Barclays
$395 $295
2/16/18	Downgrades	Buy Hold	X
BIIB Biogen Argus
2/5/18	Reiterated	Buy		X
BIIB Biogen Mizuho
$400 $433

BIIB Biogen Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.